Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 267K | 30K | 0 |
| Gross Profit | 0 | 0 | 82K | 10K | 0 |
| Operating Income | -1M | -3M | -14M | -87K | -102K |
| EBITDA | -2M | -3M | -6M | -87K | 70K |
| Net Income | -2M | -9M | -34M | -87K | -102K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0163
+0.00% today
1Y Change
+42.36%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 251 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Wesana Health Holdings Inc. (WSNAF) is a Healthcare stock with listed on OTC. The stock last traded around $0.02 and up 42.4% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +79.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +79.1%, free cash flow +88.7% with operating margin 0.0% and ROIC 4706.5%. Stock Foundry combines WSNAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
WSNAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
WSNAF Max Drawdown
-90.36%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for WSNAF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$101.5K
-16.5% YoY
Free Cash Flow
-$117.5K
-582.2% YoY
Revenue Growth
+0.0%
EPS Growth
+79.1%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 267K | 30K | 0 |
| Gross Profit | 0 | 0 | 82K | 10K | 0 |
| Operating Income | -1M | -3M | -14M | -87K | -102K |
| EBITDA | -2M | -3M | -6M | -87K | 70K |
| Net Income | -2M | -9M | -34M | -87K | -102K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 43K | 446K | 7M | 1M | 281K |
| Total Assets | 993K | 2M | 10M | 1M | 289K |
| Total Liabilities | 1M | 969K | 2M | 1M | 7K |
| Shareholder Equity | -273K | 965K | 8M | -63K | 282K |
| Total Debt | 249K | 295K | 645K | 0 | 0 |
| Net Debt | 206K | -151K | -6M | -1M | -281K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
117K
-582.2% YoY
Capital Expenditures
0
Free Cash Flow
117K
-582.2% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-506.8%
Debt / Equity
-0.91x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.